Development Pipeline
Select programs in development, Phase 1 through Approval (removed after programs achieve approval in both US/EU)
Learn More
Novel Therapies
Select Novel Therapy programs recently approved or with potential filings in the US/EU within a specified window as outlined in the Pharmaceutical Business Review.
Learn More
2023 Key Events
Major US/EU Approvals and Submissions and Phase 2/3 Clinical Data presentations being planned or achieved for the year.
Learn More
U.S. Patent Expiry Tables
Information about our pharmaceutical patent portfolio.
Learn More